Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients

Annals of Surgical Oncology

Volumn 3, Issue 2, 1996, Pages 162-168

  Mora, Edna M ^a   Singletary, S Eva ^a,b   Buzdar, Aman U ^a   Johnston, Dennis A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Locoregional recurrence; Mastectomy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIFE TABLE; MASTECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIFE TABLES; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0030099430     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02305796     Document Type: Article

References (33)

1. Aberizk WJ, Silver B, Henderson IC, Cady B, Harris JR. The use of radiotherapy for treatment of isolated regional recurrence of breast cancer after mastectomy. Cancer 1986;58:1214-8.
2. Bedwinek JM, Lee J, Fineberg B, Ocwieza M. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 1981;47:2232-5.
3. Chen KK, Montague ED, Oswald MJ. Results of irradiation in the treatment of loco-regional breast cancer recurrence. Cancer 1985;56:1269-73.
4. Griem KL, Henderson IC, Gelman R, Ascoli D, Silver B, Recht A, Goodman RL, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987;5:1546-55.
5. Buzdar AU, McNeese MD, Hortobagyi GN, Smith TL, Kau S, Fraschini G, Hug V, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer 1990;65:394-9.
6. Fowble B, Gray R, Gilchrist K, Goodman RL, Taylor S, Tormey DC. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6:1107-17.
7. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer 1978;41: 1170-8.
8. Crowe JP Jr, Gordon NH, Antunez AR, Shenk RR, Hubay CA, Shuck JM. Local-regional breast cancer recurrence following mastectomy. Arch Surg 1991;126:429-32.
9. Janjan NA, McNeese MD, Buzdar AU, Montague ED, Oswald MJ. Management of locoregional recurrent breast cancer. Cancer 1986;58:1552-6.
10. Probstfeld MR, O'Connell TX. Treatment of locally recurrent breast carcinoma. Arch Surg 1989;124:1127-30.
11. Mendenhall NP, Devine JW, Mendenhall WM, Bland KI, Million RR, Copeland EM. Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiother Oncol 1988;12: 177-85.
12. Schwaibold F, Fowble BL, Solin LJ, Schultz DJ, Goodman RL. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991;21:299-310.
13. Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 1994;12:2071-7.
14. Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR, Fineberg B. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1992;23:285-91.
15. Buzdar AU, Hortobagyi GN, Kau S-W, et al. Breast cancer adjuvant therapy at the M. D. Anderson Cancer Center - results of four prospective studies. In: Salmon SE, ed. Adjuvant therapy of cancer VII. Philadelphia: JB Lippincott, 1993:220-5.
16. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, et al. Postoperative adjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine: a follow-up report. JAMA 1979;242:1509-13.
17. Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, et al. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide with or without bacillus Calmette-Guèrin and with or without XRT in operable breast cancer: a randomized trial. Cancer 1984;53:384-9.
18. Buzdar AU, Hortobagyi GN, Kau S-W, Smith TL, Fraschini G, Holmes FA, Hug V, et al. Doxorubicin-containing adjuvant therapy for patients with stage II breast cancer: M. D. Anderson Cancer Center experience. In: Salmon SE, ed. Adjuvant therapy of cancer VI. Philadelphia: WB Saunders, 1990:210-5.
19. American Joint Committee on Cancer. Manual for staging of cancer, 2nd ed. Philadelphia: JB Lippincott, 1978.
20. Black MM, Kwon S. Prognostic factors in breast cancer. In: Gallager HG, Leis HP Jr, Synderman RK, Urban JA, eds. The breast. St. Louis: CV Mosby, 1978:297.
21. Gehan EA. Estimating survival functions from the life table. J Chron Dis 1969;21:629-44.
22. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990;8:548-55.
23. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990;8:1207-16.
24. Hortobagyi GN. Overview of new treatments for breast cancer. Breast Cancer Res Treat 1992;21:3-13.
25. Rowinsky EK, Casenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
26. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
27. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (taxol) and docetaxel (taxotere). Cancer Treat Rev 1993;19:351-86.
28. Kiang DT, Kennedy BJ. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med 1977;87:687-90.
29. Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotrophin-releasing hormone. Endoer Rev 1986;7:89-94.
30. Pierce LJ, Lichter AS, Archer P. Indications, integration, and technical aspects of local-regional irradiation in the management of advanced breast cancer. Semin Radiat Oncol 1994;4:242-53.
31. Kroll SS, Walsh G, Ryan B, King RC. Risks and benefits of using Marlex mesh in chest wall reconstruction. Ann Plast Surg 1993;31:303-6.
32. McCormack PM, Bains MS, Burt ME, Martini N, Chaglassian T, Hidalgo DA. Recurrent mammary carcinoma failing multimodality therapy. Arch Surg 1989;124:158-61.
33. Singletary SE. Surgical management of locally advanced breast cancer. Semin Radiat Oncol 1994;4:254-9.